PCO2 IMPACT OF ANEMIA ON HOSPITALIZATION AND MORTALITY IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC KIDNEY DISEASE
Coley KC, Saul MI, Kirisci L, Smith RB University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA OBJECTIVES: To determine the influence of anemia on hospitalization and mortality in elderly patients with chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD). METHODS: We identified ambulatory patients over age 65 who had at least one outpatient hemoglobin lab between 1998 to 2002. Patients were identified using a medical record data repository from a large health care system in Western Penn-sylvania. COPD was identified using ICD-9 coding and CKD was defined as having at least 2 GFR measurements <60 ml/min separated by at least 3 weeks. Demographic, comorbidity, laboratory, and visit data were collected. Anemia was defined by WHO criteria as a hemoglobin <13 g/dL in males and <12 g/dL in females. Cox proportional hazard models were used to estimate the hazard ratio of first hospitalization and death by adjusting for demographics and comorbidities. Hazard ratios of anemic and non-anemic cohorts were compared. RESULTS: There were 895 elderly patients (47% male; 87% white) identified with COPD and CKD. Comorbidities included hypertension in 86%, heart failure in 78%, and diabetes in 54% of patients. Males had higher rates of anemia (58% versus 49%, p = 0.006). Compared to non-anemic patients, those with anemia had a higher rate of hospitalization within 1 year (hazard ratio = 1.34, 95% CI: 1.14, 1.57). Mean inpatient days during the study timeframe were higher for anemic patients (51 verses 44 days, p = 0.03). The adjusted hazard ratio for all-cause mortality in anemic patients was 1.52 (95% CI: 1.18, 1.99). Mean survival time for anemic patients was 44.5 months and for non-anemic patients was 48.9 months (p = 0.003). CONCLUSIONS: The results of this study suggest that anemia is associated with a significant increase in the risk of hospitalization and death in elderly patients with COPD and CKD after adjusting for other comorbidities. The effect of anemia management on these outcomes should be evaluated in prospective clinical trials. In preparation for exploring the potential costeffectiveness of inhaled corticosteroids (ICS) for the treatment of chronic obstructive pulmonary disease (COPD), we explored the costs and outcomes of patients with COPD in the presence of missing data. METHODS: Using data on 751 patients enrolled in the ISOLDE randomized controlled trial that received either fluticasone propionate or placebo, the outcomes studied were COPD exacerbations, successfully treated weeks, rate of decline in FEV1, costs, survival and health status. In line with the original clinical analysis, costs and outcomes were estimated using a hierarchical multilevel model assuming data were missing at random. Further analyses explored the use of quality-adjusted survival techniques for health outcomes as well as multiple imputation methods to address missing data issues. RESULTS: In the base case analysis we estimated the incremental costs of ICS versus placebo to be £900 (95% confidence interval (CI): 100; 1700) and the additional effect of 0.59 (CI: 0; 1.3) exacerbations avoided and 3 (CI: 1.7; 4.5) successfully treated weeks. We explored the robustness of these results to alternative assumptions in extensive sensitivity analysis. While survival was higher
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